September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
When Statin Guidelines Collide: 5 Questions on 2 Approaches to Primary CVD Prevention
Guidelines on primary ASCVD prevention from the USPSTF and the AHA/ACC/Multisociety differ on why and when to initiate a statin. Try the 5-question quiz.
Daily Dose: The BMI vs Body Fat Debate
Your daily dose of clinical news you may have missed.
Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance
AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.
Daily Dose: T2D Raises Risk for Hepatic Decompensation, Hepatocellular Carcinoma in Patients with NAFLD
BMI vs body fat; menopause and martinis; statin guidelines collide; +2 - The Five for Friday
Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.
The BMI vs Body Fat Debate: Study Suggests One-Third of People with Normal BMI are Obese
In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.
Menopause and ETOH: Beware the Tipping Point
Binge drinking among women going through menopause has been on the rise, research indicates, making clinical inquiry in this population particularly important.
In Patients with NAFLD, Type 2 Diabetes Significantly Ups Risk for Hepatic Decompensation, Hepatocellular Carcinoma
In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .
Expert to Primary Care: Use these "ABCs" to Manage Obesity and T2D
The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.
Inclisiran Label Expanded to Include Primary Prevention Population
The expanded indication widens the patient population eligible for the novel siRNA therapy to include high-risk patients on maximum statin Rx who have not had a CV event.
Statins Appear Beneficial for CV Outcomes in Primary Prevention Patients with HTN without CVD or Diabetes
In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.
Daily Dose: Loneliness and CVD Risk in Patients with Diabetes
Daily Dose: Childhood Glycemic Measures as Predictors of Diabetes-Related Complications
Treating Obesity & T2D: Experts Say Simultaneous, Early Intervention is Key
Early intervention is crucial to help prevent complications in patients with obesity and type 2 diabetes. Two experts explain more, here.
Daily Dose: Pegozafermin in Patients with NASH
Loneliness Linked to Greater Risk for CVD in Individuals with Diabetes
The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.
ADA Updates Standards of Care, Adding Teplizumab for Delay of T1D, Emphasizing Hepatic Disease Management
The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.
Pegozafermin Shows Early Promise in NASH: Phase 2b ENLIVEN Trial Findings
Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.
FDA Awards De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Decline in Kidney Function in Adults with Type 2 Diabetes and Early-Stage Kidney Disease
KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.
Glycemic Screening in Childhood May Predict Diabetes-Related Complications, According to New Data
ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.
Daily Dose: HF, CV Benefit of SGLT-2 Inhibition Consistent in T2D, CDK, HF
Health Inequities in Persons with Obesity & Type 2 Diabetes Exacerbated During COVID-19 Pandemic
Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.
Studies of Novel, Highly Effective Antiobesity Medications Headline 83rd ADA Scientific Sessions
Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.
Daily Dose: Bempedoic Acid Reduces Risk for MACE in Primary Prevention Population
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes
ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
Daily Dose: Novel Drug Therapy for Obesity Shown Effective Up to 46 Weeks
Oral Semaglutide 50 mg May be Effective Option for Obesity Treatment, According to OASIS 1 Study Authors
ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.
Daily Dose: Tirzepatide Leads to 15% Weight Loss in Adults with Obesity, T2D